Andrea Luca Rodomonte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Luca Rodomonte has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Maria Cristina Gaudiano
Chemical Medicines Unit, National Centre for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
6 shared publications - Monica Bartolomei
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
6 shared publications - Eleonora Antoniella
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
5 shared publications - Luisa Valvo
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
5 shared publications - Livia Manna
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
4 shared publications - Paola Bertocchi
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
4 shared publications
Latest Publications
- Open Access
- 7 February 2024
- Published by MDPI AG in Separations
- Vol. 11 (2) , 54
A New Ultra High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method to Monitor 1-Amino-4-Methyl-Piperazine and 1-Methyl-4-Nitroso-Piperazine in Rifampicin Hydrolysis: A Standard Addition Approach to Quantify Nitrosamine in Rifampicin
1-amino-4-methyl-piperazine (AMP) is both a starting material for the synthesis of rifampicin (RIF) and a degradation product of RIF hydrolysis. 1-methyl-4-nitroso-piperazine (MNP) is an oxidation product of AMP as well as a potentially genotoxic N-nitrosamine. The EMA and FDA have approved an ad interim limit of 5 ppm for MNP in RIF drug products. As in-house methods for the analysis of MNP in RIF use a wide range of conditions for mobile phases and sample diluents, we decided to investigate whether these conditions affect the formation of MNP and AMP. A UHPLC-MS/MS method was developed to simultaneously quantify AMP and MNP during RIF hydrolysis in buffered aqueous solutions at different pH levels. Analyses were performed in MRM mode; separations were carried out on an InfinityLab Poroshell HPH-C18 (100 mm, 2.1 mm i.d., particle size 1.9 μm). In aqueous RIF solutions, the content of AMP and MNP increases with time; at different pHs, the concentration of AMP increases much faster in acidic than in basic solutions; and the increase in MNP can be reduced by the addition of ascorbic acid. To avoid an overestimation of MNP, water should not be used as a diluent in RIF sample preparations. Methanol is a more suitable diluent than water. A standard addition method has been validated for the quantification of MNP in RIF drug substances.
- 7 February 2024
- Published by MDPI AG in Separations
- Vol. 11 (2) , 54
Open AccessA New Ultra High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method to Monitor 1-Amino-4-Methyl-Piperazine and 1-Methyl-4-Nitroso-Piperazine in Rifampicin Hydrolysis: A Standard Addition Approach to Quantify Nitrosamine in Rifampicin
1-amino-4-methyl-piperazine (AMP) is both a starting material for the synthesis of rifampicin (RIF) and a degradation product of RIF hydrolysis. 1-methyl-4-nitroso-piperazine (MNP) is an oxidation product of AMP as well as a potentially genotoxic N-nitrosamine. The EMA and FDA have approved an ad interim limit of 5 ppm for MNP in RIF drug products. As in-house methods for the analysis of MNP in RIF use a wide range of conditions for mobile phases and sample diluents, we decided to investigate whether these conditions affect the formation of MNP and AMP. A UHPLC-MS/MS method was developed to simultaneously quantify AMP and MNP during RIF hydrolysis in buffered aqueous solutions at different pH levels. Analyses were performed in MRM mode; separations were carried out on an InfinityLab Poroshell HPH-C18 (100 mm, 2.1 mm i.d., particle size 1.9 μm). In aqueous RIF solutions, the content of AMP and MNP increases with time; at different pHs, the concentration of AMP increases much faster in acidic than in basic solutions; and the increase in MNP can be reduced by the addition of ascorbic acid. To avoid an overestimation of MNP, water should not be used as a diluent in RIF sample preparations. Methanol is a more suitable diluent than water. A standard addition method has been validated for the quantification of MNP in RIF drug substances.
- 27 April 2010
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (2) , 215-220
Counterfeit drugs detection by measurement of tablets and secondary packaging colour
- 27 April 2010
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (2) , 215-220
Counterfeit drugs detection by measurement of tablets and secondary packaging colour
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 477-481
Different crystal morphologies arising from different preparation methods of a same polymorphic form may result in different properties of the final materials: The case of diclofenac sodium trihydrate
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 477-481
Different crystal morphologies arising from different preparation methods of a same polymorphic form may result in different properties of the final materials: The case of diclofenac sodium trihydrate
- 11 September 2006
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 42 (1) , 56-63
Uncertainty evaluation in the chloroquine phosphate potentiometric titration: Application of three different approaches
- 11 September 2006
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 42 (1) , 56-63
Uncertainty evaluation in the chloroquine phosphate potentiometric titration: Application of three different approaches